PDCD1 and non-small cell lung carcinoma: We observed this particular issue in three different trials that had to be terminated or amended to phase II, in response to the approval of PD-1 (programmed cell death-1) inhibitors (pembrolizumab, nivolumab) for the treatment of advanced NSCLC [20,24,25].